213598-10-8

Basic information

• Product Name: METHYL 3-BROMO-4-ISOPROPOXYBENZOATE
• Synonyms: METHYL 3-BROMO-4-ISOPROPOXYBENZOATE
• CAS NO: 213598-10-8
• Molecular Formula: C₁₁H₁₃BrO₃
• Molecular Weight: 273.12
• Mol File: 213598-10-8.mol
• Article Data: 10

Chemical Properties

• Boiling Point: 321.561 °C at 760 mmHg
• Flash Point: 148.275 °C
• Appearance: /
• Density: 1.359
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: METHYL 3-BROMO-4-ISOPROPOXYBENZOATE(CAS DataBase Reference)
• NIST Chemistry Reference: METHYL 3-BROMO-4-ISOPROPOXYBENZOATE(213598-10-8)
• EPA Substance Registry System: METHYL 3-BROMO-4-ISOPROPOXYBENZOATE(213598-10-8)

Safety Data

• Hazardous Substances Data: 213598-10-8(Hazardous Substances Data)

Usage

General Description

Methyl 3-Bromo-4-Isopropoxybenzoate is a chemical compound with the molecular formula C11H13BrO3. This white to beige colored substance mainly falls under the category of benzene and substituted derivatives. Its applications are majorly found in various scientific and industrial sectors. Being a halogenated ester, the compound can be used in organic synthesis processes where it typically reacts with other substances to form new compounds. Despite its vast usefulness, one must always exercise caution while handling this chemical as its physical and chemical properties are not fully documented, and specific safety measures may be necessary for its handling and use.

Upstream product

• 29415-97-2 methyl 3-bromo-4-hydroxybenzoate 
• 75-26-3 isopropyl bromide 
• 75-30-9 2-iodo-propane 
• 14348-41-5 3-bromo-4-hydroxy-benzoic acid 

Downstream Products

• 213598-11-9 methyl 3-cyano-4-[(1-methylethyl)oxy]benzoate 
• 213598-20-0 3-Bromo-4-iso-propoxybenzoic Acid 
• 1163142-17-3 4-isopropoxy-3-(methylsulfonyl)benzoic acid 
• 1312035-13-4 4-[5-(5-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-6-(methyloxy)-1H-indazol-1-yl]butanoic acid 
• 1312009-60-1 4-[5-(5-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-6-ethyl-1H-indazol-1-yl]butanoic acid 
• 1312009-58-7 4-[5-(5-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-6-methyl-1H-indazol-1-yl]butanoic acid 
• 1312009-57-6 4-[6-chloro-5-(5-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-1H-indazol-1-yl]butanoic acid 
• 1312009-30-5 5-[3-(1H-indazol-4-yl)-1,2,4-oxadiazol-5-yl]-2-[(1-methylethyl)oxy]benzonitrile 
• 1312009-26-9 ethyl 4-[5-(5-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-6-(methyloxy)-1H-indazol-1-yl]butanoate 
• 1312009-61-2 ethyl 4-[5-(5-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-6-ethyl-1H-indazol-1-yl]butanoate 
• 1312009-23-6 ethyl 4-[5-(5-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-6-methyl-1H-indazol-1-yl]butanoate 
• 1312009-22-5 ethyl 4-[6-chloro-5-(5-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-1H-indazol-1-yl]butanoate 
• 1072947-68-2 5-[3-(1H-indazol-5-yl)-1,2,4-oxadiazol-5-yl]-2-[(1-methylethyl)oxy]benzonitrile 
• 258273-31-3 3-cyano-4-isopropoxybenzoic acid 

Relevant articles and documents

Discovery of selective HDAC/BRD4 dual inhibitors as epigenetic probes

According to the binding mode of ABBV-744 with bromodomains and the cape space of HDAC, the novel selective HDAC/BRD4 dual inhibitors were designed and synthesized by the pharmacophore fusion strategy. Evaluating the biomolecular activities through SARs exploration identified three kinds of selective dual inhibitors 41c (HDAC1/BRD4), 43a (pan-HDAC/BRD4) and 43d (HDAC6/BRD4(BD2)), whose target-related cellular activities in MV-4-11 cells were also confirmed. Significantly, the selective dual inhibitor 41c (HDAC1/BRD4) exhibited synergistic effects against MV-4-11 cells, which strongly induced G0/G1 cell cycle arrest and apoptosis, and the first HDAC6/BRD4(BD2) dual inhibitor was found. This study provides support for selective HDAC/BRD4 dual inhibitors as epigenetic probes based on pyrrolopyridone core for the future biological evaluation in different cancer cell lines.

SPIRO COMPOUND AND USE THEREOF

The present disclosure relates to a series of tricyclic compounds and the use thereof as receptor agonists of sphingosine-1-phosphate subtype 1 (S1P1), and in particular relates to compounds as shown in formula (I) or pharmaceutically acceptable salts the

OXADIAZOLE SUBSTITUTED INDAZOLE DERIVATIVES FOR USE AS SPHINGOSINE 1-PHOSPHATE 1 (S1P1) RECEPTOR AGONISTS

Oxadiazole substituted indazole derivatives of formula (I) or pharmaceutical salts thereof having pharmacological activity, processes for their preparation, pharmaceutical compositions containing them and their uses in the treatment of various disorders mediated by S1P1 receptor are disclosed.